Advanced searches left 3/3

Simvastatin - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 09 September 2022

* If you want to update the article please login/register

Comparison of Effects of Simvastatin Versus Ezetimibe on Intracellular Lipid and Inflammation in Obese Subjects

Atherosclerosis is the most common cause of cardiovascular disease. Vimvastatin and ezetimibe are mixed in a combination of actions on cholesterol absorption from the gut and hepatic cholesterol biosynthesis, which has a huge effect on lower LDLc levels. Following acute inflammatory changes induced by cream intake, we have found that Vytorin has a potent anti-inflammatory activity in the obese in the fasting state and following acute inflammatory changes in the obese. Compared to simvastatin alone, the IMPROVE-IT trial, which investigated the benefits of adding ezetimibe to simvastatin, revealed only a modest additional benefit of ezetimibe. We will therefore look into the anti-inflammatory activities of the two components of Vytorin by comparing the effects of simvastatin and ezetimibe on intracellular lipid and inflammation in obese patients to determine which of the two components is responsible for the specific combination of these effects.

Source link: https://clinicaltrials.gov/ct2/show/NCT04638400


A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Following 14 days of pre-surgical therapy, we will find out if the addition of simvastatin to letrozole will result in a decrease of Ki67, a biomarker of tumor formation, in postmenopausal women with stage I-III, hormone receptor positive, HER2 negative breast cancer. Based on the determination of the immune subtype content in the tissue by multiplex immunofluorescence, we can determine if the addition of simvastatin to letrozole elevates immune activation from pre- to post-treatment. A correlation was found between response defined per percent change in Ki-67 and the percentage of tissue immune biomarkers CD8 and FOXp3. Based on the Patient-Reported Outcomes Measurement System from pre- to post-treatment, it is possible to determine if the addition of simvastatin to letrozole will cause more pain than placebo alone. Multiplex immunofluorescence testing showed that changes in the levels of these blood-based biomarkers correlate with changes in immune activation, which can be correlated with changes in immune activation. Based on Ki67 results, evaluate HMG-CoA Reductase immunohistochemistry in both arms of the trial to see if there is a correlation with changes in antiproliferative response. Patients are treated with letrozole orally every day, and simvastatin PO QD for 14 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive letrozole PO QD for 14 days in the absence of disease progression or unacceptable toxic toxicity.

Source link: https://clinicaltrials.gov/ct2/show/NCT05464810

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions